The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | A meta-analysis of real-world studies comparing liso-cel to axi-cel in R/R LBCL
In this video, Fernando Gibran-Nunes, MD, Hospital Sirio-Libanês, São Paulo, Brazil, briefly discusses the results of a meta-analysis comparing the efficacy and safety of lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There are no head-to-head trials comparing axi-cel and liso-cel, so we gathered five real-world studies about these two drugs and compared them. And our findings suggest that they have a very similar efficacy profile, so they have a very high response rate, both of them, but regarding safety outcomes, liso-cel showed a more secure profile with less all grade CRS and all grade ICANS...
There are no head-to-head trials comparing axi-cel and liso-cel, so we gathered five real-world studies about these two drugs and compared them. And our findings suggest that they have a very similar efficacy profile, so they have a very high response rate, both of them, but regarding safety outcomes, liso-cel showed a more secure profile with less all grade CRS and all grade ICANS.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
